Neuroglobin as a novel biomarker for predicting poor outcomes in aneurysmal subarachnoid hemorrhage.

Neuroglobin as a novel biomarker for predicting poor outcomes in aneurysmal subarachnoid hemorrhage.

World Neurosurg. 2018 May 05;:

Authors: Cai H, Zheng S, Cai B, Yao P, Ding C, Chen F, Kang D

Abstract
OBJECTIVE: Neuroglobin (Ngb) has a high affinity for oxygen and helps prevent hypoxic-ischemic brain damage. In this paper, we analyzed the relationship between Ngb levels and clinical outcomes of aneurysmal subarachnoid hemorrhage (aSAH).
METHODS: Serum Ngb levels were measured in 58 patients with aSAH and 27 controls using enzyme-linked immunosorbent assay. To continuously assess aSAH, we measured serum Ngb levels on days 1, 2, 3, 5 and 7 after aSAH. Clinical data were collected using the Hunt & Hess Scale, Glasgow Coma Scale (GCS), World Federation of Neurological Surgeons (WFNS) scale and modified Fisher scale. Clinical outcomes included 6-month mortality and 6-month unfavorable outcomes (modified Rankin Scale (mRS) score of 3-6).
RESULTS: Serum Ngb levels increased after aSAH, peaked on day 2, and then gradually decreased, and serum Ngb levels on admission were higher in the patient group than in the control group (7.67 ± 2.56 ng/mL vs. 6.45 ± 0.88 ng/mL, P < 0.05). Multivariate logistic regression analysis indicated that serum Ngb levels on day 2 after aSAH were independently related to 6-month mortality (OR = 0.265, 95% CI = 0.094-0.747, P < 0.05) and 6-month unfavorable outcomes (OR = 1.919, 95% CI = 1.158-3.180, P < 0.05), and receiver operating characteristic (ROC) curve analysis showed that serum Ngb levels on day 2 predicted 6-month mortality and 6-month unfavorable outcomes with areas under the curve (AUCs) of 0.893 (P < 0.05; 95% CI, 0.812-0.974) and 0.818 (P < 0.05; 95% CI, 0.691-0.954), respectively, based on the best thresholds.
CONCLUSIONS: Serum Ngb levels on day 2 after aSAH were strongly associated with poor outcomes in aSAH, suggesting that Ngb may be a novel biomarker for predicting poor outcomes in aSAH.

PMID: 29738858 [PubMed - as supplied by publisher]

https://ift.tt/2K5Oa2F